Elsevier

Magnetic Resonance Imaging

Volume 17, Issue 2, February 1999, Pages 291-299
Magnetic Resonance Imaging

Original Contributions
A 1H MRS study of probable Alzheimer’s disease and normal aging: implications for longitudinal monitoring of dementia progression

https://doi.org/10.1016/S0730-725X(98)00168-4Get rights and content

Abstract

In order to evaluate the capability of 1H MRS to monitor longitudinal changes in subjects with probable Alzheimer’s disease (AD), the temporal stability of the metabolite measures N-acetylaspartate and N-acetylaspartylglutamate (NA), total Creatine (Cr), myo-Inositol (mI), total Choline (Chol), NA/Cr, mI/Cr, Chol/Cr and NA/mI were investigated in a cohort of normal older adults. Only the metabolite measures NA, mI, Cr, NA/Cr, mI/Cr, and NA/mI were found to be stable after a mean interval of 260 days. Relative and absolute metabolite measures from a cohort of patients with probable AD were subsequently compared with data from a sample of normal older adult control subjects, and correlated with mental status and the degree of atrophy in the localized voxel. Concentrations of NA, NA/Cr, and NA/mI were significantly reduced in the AD group with concomitant significant increases in mI and mI/Cr. There were no differences between the two groups in measures of Cr, Chol, or Chol/Cr. Significant correlations between mental status as measured by the Mini-Mental State Examination and NA/mI, mI/Cr and NA were found. These metabolite measures were also significantly correlated with the extent of atrophy (as measured by CSF and GM composition) in the spectroscopy voxel.

Introduction

In addition to structural and volumetric MRI measures, single voxel proton magnetic resonance spectroscopy (1H MRS) is currently being investigated as an additional non-invasive tool to monitor neurodegenerative diseases. Localized 1H MRS can detect N-acetyl containing compounds (NA), consisting primarily of N-acetylaspartate (NAA) and, to a lesser extent, N-acetylaspartylglutamate (NAAG). Although difficult to resolve in vivo, these compounds are important putative markers for neuronal viability.1, 2, 3 Membrane biosynthesis and metabolism can be investigated by monitoring creatine, phosphocreatine (Cr) and choline containing compounds (Chol), namely free choline, phosphocholine and glycerophosphocholine.2, 3 The organic osmolyte myo-inositol (mI) is a possible glial cell marker4 and has been postulated as a breakdown product of abnormal cerebral inositol polyphosphate–inositol phosphatide metabolism.5

With respect to Alzheimer’s disease (AD), the majority of 1H MRS studies have reported a reduction in the concentration of NA relative to age-matched normal control subjects. The reduction in the NA levels have been reported either as an absolute measurement or as a decrease in the metabolite ratios of NA/Cr and NA/Cho.6, 7, 8, 9, 10, 11, 12, 13, 14, 15 In addition, an increase in the concentration of mI has been observed.8, 9, 10, 14 No significant differences in the levels of Chol or Chol/Cr have been reported between the two groups.6, 7, 8, 9, 10, 11, 12, 14 The majority of studies using absolute metabolite measures have found no change in the concentration of Cr in the brains of AD patients,6, 8, 9, 15 although one investigation has reported a significant reduction compared with normal controls.10

Despite the increasing number of 1H MRS investigations of neurodegenerative diseases, there is a paucity of data demonstrating the reproducibility and temporal stability of the metabolite measures in normal populations. Of the few studies that have been published, all have reported data acquired from younger subjects. Marshall et al.16 reported coefficients of variation (CV) for “between days” measurements of NA/Cr and Chol/Cr of between 10.1 and 22.6 percent. Simmons et al.17 reported CV values for these ratios of 4.61 and 7.12%, respectively. Both of these studies employed long echo time (TE of 135 ms) spectroscopy protocols. Two reproducibility studies have been reported using short TE MRS (TE < 30 ms). Narayana et al.18 presented grouped data with little information regarding intrasubject reproducibility, while those reported by Kreis et al.19 were presented as a “systematic trend” of variability of approximately 5%. To the best of our knowledge, no study has yet investigated the reproducibility and stability of single voxel 1H MRS measurements in a cohort of normal older adults.

A coherent approach to the analysis of repeated 1H MRS measurements is yet to be proposed and implemented. In this paper, we utilize the coefficient of variation (CV) to assess measurement precision, and the Pearson product moment correlation coefficient20 (r) to quantify the relationship between metabolite data from two longitudinal spectral acquisitions in normal subjects.22 Since spectra are acquired from the same subject on two or more occasions, it is often assumed that differences between spectral measurements are solely due to measurement error. However, the length of time between acquisitions may also be a significant contributing variable. For example, Marshall et al.16 acquired spectra over four days, whereas Narayana et al.18 acquired data over a six-month period. Determining the consistency of spectra obtained over long intervals involves an assumption that the neuronal compounds of interest themselves do not change, i.e., that they are stable. This assumption may or may not be valid. In this paper, we use the term reproducibility to refer to data obtained within the same day and conversely, use the term stability to refer to data obtained over intervals greater than 24 h.

The relationship between relative or absolute cerebral metabolite measures and cognitive dysfunction in AD patients has only recently been addressed. Significant correlations between NA/Chol, NA, and Mini Mental State Exam (MMSE)21 scores have been reported.14, 10, 22 In the present study, we report reproducibility and stability data for both relative and absolute measures of NA, mI, Cr, and Chol in a cohort of normal older adults. In addition, we report differences in these neuronal compounds between patients with probable AD and control subjects. To further establish the efficacy of 1H MRS in monitoring AD progression, relative and absolute metabolite measures were correlated with MMSE scores and indices of atrophy (as measured by CSF and GM composition) in the localized voxel.

Section snippets

Materials and methods

Thirty-three normal older adults (18 male, 15 female) and thirteen subjects with probable Alzheimer’s disease who volunteered for a longitudinal study of Alzheimer’s disease and normal aging conducted at the Center for Magnetic Resonance, University of Queensland participated in the study. A subgroup of twenty-seven of the normal subjects (16 male, 11 female, mean age 73.6 ± 3.7 years) were involved in the reproducibility and stability study of relative metabolite measures. From this group

Results

Spectra from a representative subject are shown in Fig. 2. Spectra A and B, representing the first and second time points, respectively, were acquired within the same day. Spectrum C represents a longitudinal acquisition obtained 180 days after the initial same day scans. The means and standard deviations for the metabolite measures NA, mI, Cr, Chol, NA/Cr, mI/Cr, Chol/Cr and NA/mI for each time point are presented in Table 1. There was no significant difference between the mean values of

Discussion

The absolute metabolite concentrations and ratios reported in this study are comparable with those reported by Moats et al.8 and Provencher27 from gray matter voxels in the parietal cortex. In addition, the coefficient of variation analysis of the spectroscopic data reveals a level of reproducibility equal to, or better than those reported in the literature to date.16, 17, 18 However, this interpretation is based on the calculation of mean metabolite ratios and standard deviations over all time

Acknowledgements

This study was supported by a grant from SmithKline Beecham Pharmaceuticals, UK. We would like to thank all subjects who participated in this study and RN Jenny Whitehead and RN Anne Maree Elliott for their assistance.

References (39)

  • B.L Miller

    A review of chemical issues in 1H NMR spectroscopyN-acetyl-aspartate, creatine and choline

    NMR Boimed

    (1991)
  • J Vion–Dury et al.

    What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy?

    J. Neurol.

    (1994)
  • B.D Ross

    The biochemistry of living tissuesExamination by MRS

    NMR Biomed

    (1991)
  • C.E Stokes et al.

    Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains

    J. Neurochem.

    (1987)
  • P Christiansen et al.

    Reduced N-acetyl-aspartate content in the frontal part of the brain in patients with probable Alzheimer’s disease

    Magn. Reson. Imaging

    (1995)
  • B.L Miller et al.

    Alzheimer diseaseDepiction of increased myo-inositol with proton MR spectroscopy

    Radiology

    (1993)
  • R.A Moats et al.

    Abnormal cerebral metabolite concentrations in patients with probable Alzheimer’s disease

    Magn. Reson. Med.

    (1994)
  • T Shonk et al.

    Probable Alzheimer disease. Diagnosis with proton MR spectroscopy

    Radiology

    (1995)
  • W Huang et al.

    Correlation of brain metabolite concentration with dementia severity in Alzheimer diseaseA quantitative in vivo 1H MRS study

  • Cited by (122)

    • <sup>1</sup>H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults

      2022, Neurobiology of Aging
      Citation Excerpt :

      While the presence of AD pathologies in a proportion of cognitively unimpaired older adults is confirmed, our understanding of the biological consequences of these pathologies in cognitively unimpaired older adults is limited. Proton (1H) magnetic resonance spectroscopy (MRS) provides non-invasive measurements of the alterations in brain biochemistry associated with early features of neurodegeneration (Kantarci et al., 2008; Rose et al., 1999), and potentially of tau-related pathology in early AD (Chen et al., 2019). The applications of 1H MRS in central nervous system disorders have been described (Oz et al., 2014).

    • MR approaches in neurodegenerative disorders

      2018, Progress in Nuclear Magnetic Resonance Spectroscopy
    • Lower brain and blood nutrient status in Alzhiemer's disease: Results from meta-analyses

      2017, Alzheimer's and Dementia: Translational Research and Clinical Interventions
    View all citing articles on Scopus
    View full text